血浆脂肪细胞因子Chemerin及炎性因子TNF-α与儿童非酒精性脂肪性肝病的相关性

摘要/Abstract

摘要： 目的探讨血浆脂肪细胞因子Chemerin及炎性因子TNF-α与儿童非酒精性脂肪性肝病(NAFLD)的相关性。方法 50例明确诊断NAFLD患儿为观察组,50名健康体检儿童为对照组。分别测量和计算两组患儿身高、体质量、腰围、臀围、体质指数(BMI)及腰臀比等指标,同时检测丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆固醇(TC)、总甘油三酯(TG)、Chemerin及肿瘤坏死因子-α(TNF-α)水平。比较两组患儿上述指标的差异,同时分析其与疾病的相关性。结果观察组患儿在BMI、腰围、臀围、腰臀比、ALT、AST、TG、TC、Chemerin及TNF-α等指标方面均明显高于对照组患儿,差异有统计学意义(P＜0.05)。Logistic回归分析提示ALT、TG、BMI、Chemerin及TNF-α与非酒精性脂肪肝相关。线性回归结果提示Chemerin与TNF-α间呈正相关关系(R²=0.6171,P＜0.01)。结论 Chemerin与TNF-α的异常表达可能是参与儿童NAFLD的发病重要因素。

关键词: 非酒精性脂肪肝, 儿童, Chemerin, 肿瘤坏死因子-α

杨思谋, 李少雄, 王岳, 庄太平, 符辉. 血浆脂肪细胞因子Chemerin及炎性因子TNF-α与儿童非酒精性脂肪性肝病的相关性[J]. 肝脏, 2018, 23(6): 535-537.

参考文献

[1] Assuncao SNF, Sorte NCB, Alves CD, et al. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update. Nutr Hosp,2017,34: 727-730.
[2] Africa JA, Behling CA, Brunt EM, et al. In children with nonalcoholic fatty liver disease, zone 1 steatosis is associated with advanced fibrosis. Clin Gastroenterol Hepatol,2018, 16: 438-446.e1.
[3] Schwimmer JB, Lavine JE, Wilson LA, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology,2016,151: 1141-1154.
[4] 刘倩,陈虹,朱庆龄,等. 学龄期儿童肥胖相关性脂肪肝及血脂代谢异常对照研究. 中国儿童保健杂志,2014,22: 788-790, 794.
[5] Manning P, Murphy P, Wang K, et al. Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study. J Magn Reson Imaging,2017, 46: 1149-1158.
[6] Pawar SV, Zanwar VG, Choksey AS, et al. Most overweight and obese Indian children have nonalcoholic fatty liver disease. Ann Hepatol,2016,15: 853-861.
[7] 吴素虹,周罗根. 儿童非酒精性脂肪肝病患儿血浆脂钙素-2、炎症因子CRP水平的变化. 实用临床医药杂志,2014,18: 178-179.
[8] Sarkar M, Baffy G. Perinatal programming of adolescent nonalcoholic fatty liver disease: A case for gender inequality? Hepatology,2018, 67: 7-9.
[9] Ito D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care,2017, 40: 1364-1372.
[10] Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis,2015,47: 181-190.
[11] Hamza RT, Elkabbany ZA, Shedid AM, et al. Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome. Arch Med Res,2016,47: 541-549.
[12] Farhangi MA, Alipour B, Jafarvand E, et al. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res,2014,45: 589-595.
[13] Neuman MG, Cohen LB, Nanau RM. Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol,2014,28: 607-618.
[14] Wang YL, Liu LJ, Zhao WH, et al. Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med,2015,2015:715638.

编辑推荐 0

Metrics

阅读次数

全文

378

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	378

来源	本网站	其他网站

次数	376	2
比例	99%	1%

摘要

149

最新录用	在线预览	正式出版

0	0	149

	来源	本网站

	次数	149
	比例	100%